MedTrace Logo

HER-2 Expression in Pancreatic Duct Adenocarcinoma

NCT06055647 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2023-09-28

No results posted yet for this study

Summary

Pancreatic duct adenocarcinoma is a highly aggressive carcinoma that is associated with a poor prognosis. Detection of novel biological markers that are specifically over expressed in pancreatic duct adenocarcinoma and their subsequent targeting by anti cancer therapeutic modalities may improve patient's survival.

Conditions

  • Pancreatic Adenocarcinoma

Interventions

GENETIC

immunohistochemical approach

Formalin-fixed, Paraffin-embedded tissue blocks of pancreatic duct adenocarcinoma will be stained by anti HER-2, by immunohistochemical approach.

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-08-31
Completion
2020-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06055647 on ClinicalTrials.gov